Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xolair’s Price Discount For NICE Is Ominous Sign For Older Products

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis essentially makes volume trade-off in the most recent NICE assessment, adding a claim for ages 6-11 but offering pricing concessions as well; if the firm’s experience is any indication, even older products that come under NICE’s cost-effectiveness scrutiny will need discounts and additional data to stay in the authority’s good graces.


Related Content

German State Court Ruling Against Novartis Confirms Legality of HTA For Older Products
U.K.’s NICE Backs Esbriet, Xolair And Orencia After Getting Price Discounts
Germany's G-BA Sets Out Financial-Based Criteria For Assessing Drugs Already On The Market
NICE Rejects Novartis’ Xolair In Harbinger Of Cost Reevaluation Process
U.K. Provides £50 Million Extra For Cancer Drugs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts